BioSpace News Archive

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is inviting people across the country to take a “Moment for You” on Wednesday, November 16 and celebrate the biggest event of the year for BOTOX® Cosmetic.

The newly announced microsite from ZEISS Microscopy, gives visitors a glimpse of what they can interact with at SfN Neuroscience 2022, in San Diego, CA, booth 2228, from November 13 through November 16.

The US FDA granted the initiation of the phase 1 clinical trial of ‘BRE-AD01', an exosome- based therapy for atopic dermatitis.

Aristea Therapeutics announced the appointments of three experienced drug development experts to key positions as it works to progress and expand its clinical pipeline: Himanshu Patel, D.O., as Executive Medical Director, Jennifer Barnes, Ph.D., as Senior Director, Clinical Science, and Walter Frank Eng, PharmD, as Associate Director, Clinical Science.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the dosing of the first patient in the Phase 1b MAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will host a conference call and live webcast on Wednesday, November 9, 2022 at 8:30 am ET (5:30 am PT) to report third quarter 2022 financial results and provide recent corporate updates.

Clario, a healthcare technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced the release of new data that confirms its leadership as a provider of remote data collection technologies that enable decentralized and hybrid clinical trials.

LENSAR, Inc. today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate for injection.